Status:
WITHDRAWN
INSPIRE Turkey :A Research Study Looking at the Clinical Parameters Associated With Use and Discontinuation of Saxenda® in Local Clinical Practice in Turkey by Analysing Past Patient Medical Records
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Obesity
Eligibility:
All Genders
18+ years
Brief Summary
The study is investigating the use of Saxenda (liragltuide 3.0 milligrams (mg) once daily) for weight management. The primary objective is to investigate the change in body weight after initiation and...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients who have signed consent before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Patients who have polyclinic visits between 01 June 2022 and 31 October 2022 and who have received initial prescription of Saxenda® for weight management at least 52 weeks prior to study enrolment.
- Patients who have maintained treatment with Saxenda® for at least 16 weeks, without treatment break, following the initial prescription.
- Patients who have 12-month follow-up data, even if discontinued Saxenda ® treatment.
- Patients who have body weight measurement at baseline and at least 1 more body weight measurement following the Saxenda® prescription
- Age greater than or equal 18 years at the time of signing informed consent
- Exclusion criteria:
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
- Patient charts lacking any follow-up information for at least 16 weeks.
- Patients who have been treated with anti-obesity medication for last 12 weeks prior to initiation of Saxenda® treatment.
- Patients who receive GLP-1 receptor agonist for treatment of Type 2 diabetes.
- Patients who have undergone bariatric surgery or use of minimal-invasive weight loss devices (i.e. intragastric balloons, lap bands) within 1 year before starting Saxenda® treatment.
Exclusion
Key Trial Info
Start Date :
September 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 31 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05438186
Start Date
September 1 2022
End Date
October 31 2022
Last Update
January 25 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Istanbul, Turkey (Türkiye)